In our study, we found ARPC1B is significantly upregulated in gemcitabine‐resistant CSCs compared to non‐resistant CSCs, and it is also significantly elevated in pancreatic cancer samples versus normal tissues. This evidence concerns the gene ARPC1B and pancreatic neoplasm.